Tango Therapeutics Inc
TNGX
$7.33
Closing
▼-5.54%
1D
▼-25.96%
YTD
Market cap
$782.25M
52 week high
$12.99
52 week low
$2.47
Volume
205,895
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$782.25M
Analysts' Rating
STRONG BUY
Price Target (Mean)
17.6
Total Analysts
6
P/E
Operating Margin
-238.78%
Beta
0.91
Revenue Growth (Annual)
-32.89%
52 week high
$12.99
52 week low
$2.47
Div. Yield
%
EPS Annual Growth
0.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Tango Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision medicines to help patients with cancer through addressing the specific genetic alterations that fuel the cancer. Its lead program, TNG908, is a methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. It is also developing TNG462, a more potent and selective PRMT5 inhibitor with improved pharmacokinetic properties as compared to TNG908. TNG260 is a small molecule inhibitor of the CoREST deacetylase complex that reverses checkpoint inhibitor resistance in serine-threonine kinase 11 (STK11) mutant preclinical models. Its TNG348 is an allosteric inhibitor of ubiquitin-specific protease 1 (USP1) for the treatment of BRCA-mutant and other homologous recombination-deficient (HRD+) cancers.
